Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
The Tshepo Study
NCT00197613Phase 3Completed
- Sponsor
- Harvard T.H. Chan School of Public Health
- Start
- Dec 2002
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of zidovudine, lamivudine, nevirapine, efavirenz, didanosine and 1 more in human immunodeficiency virus infection (HIV) (8 arms), sponsored by Harvard T.H. Chan School of Public Health. Primary endpoints: Time to Virological failure and Time to grade 3 or higher toxicity. Started Dec 2002; status: completed.
02
Drugs
zidovudinelamivudinenevirapineefavirenzdidanosine
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT00197613.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00197613.